Objective To investigate the clinical effect of dapagliflozin in the treatment of early diabetic nephropathy.Methods 82 patients of early diabetic nephropathy admitted to Lianjiang County Hospital from July 2022 to July 2023 were selected as the study objects,and were divided into 41 cases each in the control group and the observation group by the random number table method.The control group was treated with acarbose glucose lowering and irbesartan,and the observation group was treated with dapagliflozin on the basis of the control group.After 12 weeks treated,the total effective rate of treatment,blood glucose indexes[fasting glucose plasma(FPG),2 h postprandial plasma glucose(2 hPG)],renal function[urea nitrogen(BUN),serum creatinine(SCr)]changes,and the incidence of adverse drug events in the two groups before and after treatment were compared.Results The total effective rate of treatment in the obser-vation group was 95.12%,which was higher than that of the control group(78.05%),and the difference was statisti-cally significant(χ2=5.145,P=0.023).After 12 weeks of treatment,FPG(6.94±1.20)mmol/L,2 hPG(8.13±0.62)mmol/L,BUN(6.07±0.45)mmol/L,and SCr(68.40±3.39)μmol/L in the observation group were lower than those in the con-trol group,and the differences were statistically significant(all P<0.05).The incidence of adverse drug events between the two groups was compared,and the difference was not statistically significant(P>0.05).Conclusion Dapagliflozin treatment of early diabetic nephropathy can better improve the renal function and blood glucose of patients,and im-prove the efficacy.
NETL
NSTL
万方数据
